Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxidronic acid
Drug ID BADD_D01640
Description Not Available
Indications and Usage Oxidronic acid is a diagnostic skeletal imaging agent used to demonstrate areas of altered osteogenesis in adult and pediatric patients.[L12960]
Marketing Status approved
ATC Code Not Available
DrugBank ID DB14159
KEGG ID D05296
MeSH ID C029285
PubChem ID 27304
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 71MR4V32TI
Synonyms hydroxymethanediphosphonic acid | hydroxymethanediphosphonic acid, disodium salt | disodium methane hydroxy-diphosphonate | disodium methane-1-hydroxy-1,1-diphosphonate | disodium (hydroxymethylene)diphosphonate | hydroxymethanediphosphonic acid, trisodium salt | hydroxymethanediphosphonic acid, monosodium salt | hydroxymethanediphosphonic acid, tetrasodium salt | hydroxymethanediphosphonic acid, 14C-labeled | hydroxymethylene bisphosphonate | 1,1-hydroxymethyldiphosphonate | MHDP | methylhydroxydiphosphonate
Chemical Information
Molecular Formula CH6O7P2
CAS Registry Number 15468-10-7
SMILES C(O)(P(=O)(O)O)P(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Burning sensation08.01.09.029; 17.02.06.001--
Cardiac arrest02.03.04.001-
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007-
Drug ineffective08.06.01.006--
Dysgeusia07.14.03.001; 17.02.07.003-
Dyspnoea02.11.05.003; 22.02.01.004-
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002-
Headache17.14.01.001-
Hyperhidrosis08.01.03.028; 23.02.03.004-
Hypersensitivity10.01.03.003--
Hypoaesthesia17.02.06.023; 23.03.03.081--
Hypotension24.06.03.002-
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.015--
Injection site extravasation08.02.03.002; 12.07.03.002--
Injection site pain08.02.03.010; 12.07.03.011--
Injection site warmth08.02.03.036; 12.07.03.036--
Loss of consciousness17.02.04.004--
Nausea07.01.07.001-
Pain in extremity15.03.04.010-
Pharyngeal oedema10.01.05.016; 22.04.05.003; 23.04.01.016--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012-
Tachycardia02.03.02.007--
Vomiting07.01.07.003-
Injection site swelling08.02.03.017; 12.07.03.018--
The 1th Page    1    Total 1 Pages